Title : A Retrospective Cohort Study on the Duration of Dexamethasone and Clinical Outcomes of Chronic Kidney Disease Patients on Dialysis with Severe to Critical COVID-19
Abstract:
The COVID-19 outbreak has rapidly spread and overwhelmed the health care facilities and has driven an urgent need for a drug treatment. Systemic corticosteroid has been recommended by the World Health Organization for severe and critical COVID-19 patients. The Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial has assessed the effects of potential treatments in COVID-19 patients wherein the experimental group received dexamethasone maximum of 10 days. The results of the trial have displayed a positive response for severe COVID-19 patients to dexamethasone. However, Corticosteroid use presents to be a double-edged sword with significant efficacy but with potential, serious adverse effects. The researcher assessed the duration of dexamethasone use and clinical outcomes of chronic kidney disease (CKD) patients on dialysis with severe to critical COVID-19 by comparing the efficacy of a 5-day course vs a 10-day course treatment.
A retrospective cohort study design was used to compare the clinical outcomes of CKD patients on dialysis with severe COVID-19 among patients administered with dexamethasone for 10 days vs those who received the treatment for less than 10 days. The outcomes measured were length of hospital stay, mortality, duration of patients on oxygen support and P/F ratio. The study has not accounted adverse effects of the durations of the treatment.
What will audience learn from your presentation?
1. To describe and compare the clinical profile of severe and critical COVID-19 patients with CKD who received short versus longer intravenous dexamethasone treatment
2. To determine the proportion of patients who received dexamethasone for only five days, and for 6- 10 days treatment, and to determine the median duration of dexamethasone treatment received by CKD patients with severe to critical COVID-19
3. To determine and compare the length of hospital stay, 30-day in-hospital mortality, duration of patients on oxygen support, and P/F ratio prior to discharge between patients with short versus longer dexamethasone treatment.
4. To determine whether the duration of dexamethasone treatment is associated with survival of severe to critical COVID-19 patients with CKD, after adjusting for age, sex, comorbidities, other treatments received, and vaccination status
